These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 32565050

  • 1. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, Diabetic Retinopathy Clinical Research Network.
    JAMA Ophthalmol; 2016 Aug 01; 134(8):888-96. PubMed ID: 27280850
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P, Kankaanpää E.
    Acta Ophthalmol; 2016 Nov 01; 94(7):652-656. PubMed ID: 27481048
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC.
    J Manag Care Spec Pharm; 2021 Jun 01; 27(6):743-752. PubMed ID: 34057392
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR, Clements KM, Hulbert E, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein MC.
    Acta Ophthalmol; 2016 Aug 01; 94(5):441-8. PubMed ID: 27061020
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA, American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.
    JAMA Ophthalmol; 2016 Jan 01; 134(1):95-9. PubMed ID: 26512939
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
    Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW, Williams GA.
    Ophthalmology; 2018 Apr 01; 125(4):522-528. PubMed ID: 29146306
    [Abstract] [Full Text] [Related]

  • 18. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun 01; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 19. Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
    Ruiz Ramos J, Pascual-Camps I, Cuéllar-Monreal MJ, Dolz-Marco R, Fenoll MA, Font-Noguera I, Poveda-Andrés JL, Gallego-Pinazo R.
    Arch Soc Esp Oftalmol; 2015 Dec 01; 90(12):566-71. PubMed ID: 26515015
    [Abstract] [Full Text] [Related]

  • 20. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S, Bressler NM.
    Curr Opin Ophthalmol; 2017 Nov 01; 28(6):636-643. PubMed ID: 28837425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.